Lataa...
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemo-naïve patients with unresectable malignant pleural mesothelioma
BACKGROUND: We conducted a phase I trial of cisplatin-pemetrexed-imatinib mesylate, an oral PDGFR inhibitor, in chemo-naive MPM patients. METHODS: A standard 3+3 dose-escalating trial was used with the endpoints of MTD, response rate, survival, safety/toxicity and tumor PDGFR levels. RESULTS: 17 MPM...
Tallennettuna:
| Julkaisussa: | Clin Lung Cancer |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5080907/ https://ncbi.nlm.nih.gov/pubmed/24492162 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2013.12.008 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|